Prolonged-release pirfenidone in patients with pulmonary fibrosis as a phenotype of post-acute sequelae of COVID-19 pneumonia. Safety and efficacy

One of the major concerns with post-acute sequelae of COVID-19 (PASC) is the development of pulmonary fibrosis, for which no approved pharmacological treatments exist. Therefore, the primary aim of this open-label study was to evaluate the safety and the potential clinical efficacy of a prolonged-release pirfenidone formulation (PR-PFD) in patients having PASC-pulmonary fibrosis.

Source: Respiratory Medicine - July 12, 2023 Category: Respiratory Medicine Authors: R.H. Sansores, A. Ram írez-Venegas, F. Montiel-Lopez, S. Domínguez-Arellano, L.F. Alva-Lopez, R. Falfán-Valencia, G. Pérez-Rubio, E. Olaya-López, E.O. Zavaleta-Martínez, S. Aguilar-Medina, J.C. Escobar-Alvarado, J.L. Poo, M.G. Matera, M. Cazzola Tags: Original Research Source Type: research